Mylan Appoints Rajiv Malik as Executive Vice President, Head of Global Technical Operations

Pittsburgh (ots/PRNewswire) -

Mylan Inc. (NYSE: MYL) today announced the appointment of Rajiv
Malik as Executive Vice President in charge of Global Technical
Operations. Mr. Malik has served in a similar capacity for Mylan
since the Company acquired a controlling stake in Matrix Laboratories
Limited (Matrix), where he is Chief Executive Officer, in January
2007.

As Head of Global Technical Operations, Mr. Malik will oversee the
Company's global research and development (R&D) centers and
manufacturing and distribution units, with responsibility for
enhancing and rationalizing Mylan's global supply chain and expanded
product pipeline, as well as leveraging Matrix, one of the world's
largest suppliers of active pharmaceutical ingredients, across the
enlarged company.

Mr. Malik has worked more than 24 years in the global generic
pharmaceutical industry. In addition to his role at Mylan, Mr. Malik
currently serves as Managing Director and Chief Executive Officer of
Matrix. Prior to joining Matrix in 2005, he was Head of Global
Development and Regulatory at Sandoz. He started his career in R&D at
Ranbaxy Laboratories, rising to Head of Generics R&D.

Mylan's Vice Chairman and CEO Robert J. Coury commented, "Rajiv
has been an invaluable addition to the Mylan management team since
joining us in January. Since the close of the Matrix transaction, he
has truly proven his capabilities and has been instrumental in the
successful integration of Matrix. Rajiv has built an outstanding
operational infrastructure that will allow us to capitalize on the
efficiencies, synergies and sourcing opportunities we see from
bringing together all three companies."

Mr. Malik earned his master's degree in pharmaceutical technology
from Punjab University and has more than 60 process patents to his
credit.

Mylan Inc. is one of the world's leading quality generic and
specialty pharmaceutical companies. The Company offers one of the
industry's broadest and highest quality product portfolios, a robust
product pipeline and a global commercial footprint through operations
in more than 90 countries. Through its controlling interest in Matrix
Laboratories Limited, Mylan has direct access to one of the largest
active pharmaceutical ingredient (API) manufacturers in the world.
Dey L.P., Mylan's fully integrated specialty business, provides the
Company with innovative and diversified opportunities in the
respiratory and allergy therapeutic areas.

For more information about Mylan, please visit www.mylan.com.

Web site: http://www.mylan.com

ots Originaltext: Mylan Inc.
Im Internet recherchierbar: http://www.presseportal.de

Contact:
Kris King, Mylan Inc., +1-724-514-1800